Michael Kelliher
Director/Board Member at CAPRICOR THERAPEUTICS, INC.
Net worth: 1 M $ as of 31/05/2024
Michael Kelliher active positions
| Companies | Position | Start | End |
|---|---|---|---|
| CAPRICOR THERAPEUTICS, INC. | Director/Board Member | 01/09/2023 | - |
| Independent Dir/Board Member | 01/09/2023 | - | |
| ARDELYX, INC. | Corporate Officer/Principal | 25/03/2024 | - |
Career history of Michael Kelliher
Former positions of Michael Kelliher
| Companies | Position | Start | End |
|---|---|---|---|
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Corporate Officer/Principal | 01/01/2014 | - |
Training of Michael Kelliher
| University College Cork | Undergraduate Degree |
Statistics
International
| United States | 3 |
| Ireland | 3 |
Operational
| Corporate Officer/Principal | 2 |
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| CAPRICOR THERAPEUTICS, INC. | Health Technology |
| ARDELYX, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
- Stock Market
- Insiders
- Michael Kelliher
- Experience
